Amplia Therapeutics Ltd.

As of March 31, 2026, Amplia Therapeutics Ltd. carries a market capitalization of 120.57M, placing it among publicly traded companies globally. Its enterprise value stands at 93.06M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Amplia Therapeutics Ltd.'s next confirmed earnings release is scheduled for November 27, 2026.

As of March 31, 2026, Amplia Therapeutics Ltd. has 513.07M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Amplia Therapeutics Ltd. maintains a current ratio of 19.78, meaning it holds 19.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.86, indicating moderate leverage, while an interest coverage ratio of -753.39 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Amplia Therapeutics Ltd. posted a negative return on equity (ROE) of -25.48, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -23.94, reflecting losses generated across the asset base.

As of the close on October 22, 2026, Amplia Therapeutics Ltd.'s stock has declined approximately 44.29% over the past 52 weeks. The 50-day moving average sits at 0.12, while the 200-day moving average is 0.14.

These figures cover the twelve months ended March 31, 2026. EBITDA reached -13.09M, while operating income came in at -13.18M.

As of March 31, 2026, Amplia Therapeutics Ltd. holds 27.85M in cash and equivalents against 341,111.00 in total debt, resulting in a net debt position of -27.85M. Total book value stands at 39.47M, with working capital of 31.37M providing operational flexibility.

These figures cover the twelve months ended March 31, 2026.

These figures cover the twelve months ended March 31, 2026. Total shareholder yield is negative at -21.51, meaning Amplia Therapeutics Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Amplia Therapeutics Ltd.'s most recent stock split took place on November 1, 2024.